NVAX Novavax, Inc.

11.22USD-0.88%Mkt Cap: 1.85B $P/E: —

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company comme…

Key Statistics

Company
Market Cap1.85B USD
Enterprise Value1.45B USD
Revenue (TTM)413.80M USD
Gross Profit1.05B USD
Net Income (TTM)440.30M USD
Revenue/Share2.54 USD
Last Price11.22 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees749
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-69.06
PEG1.32
EV/EBITDA-14.23
EV/Revenue3.49
P/S4.51
P/B-9.78
EPS (TTM)-1.42
EPS (Forward)-0.16
52W Range
6.20070% of range13.38
52W High13.38 USD
52W Low6.200 USD
Profitability
Gross Margin93.50%
Oper. Margin-89.61%
EBITDA Margin-24.54%
Profit Margin39.19%
ROE-344.65%
ROA37.42%
Growth
Revenue Growth-76.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-244.63M USD
CapEx (TTM)6.39M USD
FCF Margin37.07%
FCF Yield8.29%
Net Debt-422.02M USD
Net Debt/EBITDA4.16
Balance Sheet
Debt/Equity-1.95
Current Ratio2.33
Quick Ratio2.23
Book Value/Sh-1.16 USD
Cash/Share4.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 10, 2019
Splits
Last Split1:20
Split DateMay 10, 2019
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.00 USD
Upside (mean)+24.8%
Target Range7.000 USD – 25.00 USD
7.000+24.8% to mean25.00
# Analysts9
Ownership
Shares Out.164.95M
Float142.58M
Insiders5.05%
Institutions68.72%
Short Interest
Short Ratio8.9d
Short % Float30.43%
Short % Out.30.24%
Shares Short49.88M
Short (prev mo.)47.49M
Technical
SMA 509.274 (+21.0%)
SMA 2008.941 (+25.5%)
Beta2.44
S&P 52W Chg16.45%
Avg Vol (30d)6.86M
Avg Vol (10d)8.24M
Technical Indicators
RSI (14)59.4
MACD0.5854
MACD Signal0.5415
MACD Hist.+0.0439
BB Upper12.01 USD
BB Middle10.47 USD
BB Lower8.929 USD
BB Width29.45%
ATR (14)0.8635 USD
Vol Ratio (20d)1.21x